products.
Navigation software and fully MRI-compatible devices
trackr.ai
navigation software
trackr.ai transforms your MRI from a diagnostic tool into a fully capable interventional platform. The system delivers a cath-lab–like experience directly inside the MRI, combining MRI-compatible devices with AI-powered navigation software for a wide range of clinical applications.
trackr.ai provides real-time, radiation-free catheter navigation with enhanced 3D visualization, enabling physicians to perform safe and precise interventions without the use of contrast agents.
By seamlessly integrating hardware and software, trackr. unlocks new possibilities for image-guided therapy—bringing greater safety, precision, and efficiency to interventional care.
The Emery Glide™ Family
EmeryGlideTM is a metal-free, sterile, disposable guide wire for the introduction and placement of a wide range of diagnostic or interventional devices.
Thanks to its advanced nanoparticle coating, the distal tip is clearly visible across all imaging modalities. EmeryGlide™ is available in multiple configurations—including straight and angled tips—and comes in various diameters to meet specific clinical needs.
EmeryGlideTM is labelled as an MR conditional product according to ASTM F2182, F2052, F2053 and F2213 standards.
We are continuously expanding our portfolio with additional MRI-compatible devices, such as catheters and accessory tools, to support a wide range of interventional procedures. Please contact us to learn more about detailed product specifications or the availability of a tailor-made access kit designed for your specific clinical needs.
technology.
trackr.
transforms MRI
From a diagnostic into an interventional modality
While MRI has delivered exceptional diagnostic performance for decades, its interventional use has been constrained by significant technical barriers. That paradigm is now shifting. AI‑driven advances in scanner technology — including real‑time imaging sequences and high‑performance low‑field systems — are laying the foundation. On the device and navigation side, Nano4Imaging’s trackr. technology enables the seamless adaptation of mainstream catheterization workflows to the demands of interventional MRI (iMRI).
trackr. comprises 3 key elements:
- EmeryGlide is the world’s first FDA cleared non-metallic, MRI-conditional guidewire, consisting of a polymer-fiberglass composit.
- Magnafy is an advanced multimodal nanoparticle composite, customized applicable to any device, creating discrete visible markers that enable clear, real-time visualization in both MRI and CT.
- trackr.ai is a proprietary deep learning algorithm validated in clinical interventional settings. It detects the patterns of Magnafy markers and track device position in real time—like GPS for the catheter—across various MRI sequences.
trackr. enables cost-efficient implementation of iMRI with superior soft-tissue contrast and real-time navigation support for accurate targeting without ionizing radiation or nephrotoxic contrast agents. This integration of imaging and intervention enhances procedural precision and may allow diagnosis and treatment within a single session. iMRI further broadens access to advanced image-guided procedures, particularly for patients not optimally served by conventional modalities. Fortunately, trackr. also has a smaller footprint than radiation-based imaging.
Better soft tissue visualization
No Radiation exposure
Real time imgaging
No need for iodinated contrast
One-stop-shop Diagnostics + therapy
Greater access to care
evidence.
Evidence-Based Patient Advantages
Interventional MRI (iMRI) represents a fundamental shift in patient care—offering precision, clarity, and safety that enables clinicians to diagnose and treat with greater confidence. For patients, this means safer procedures and earlier interventions that can transform treatment outcomes.
iMRI eliminates ionizing radiation and reduces dependence on nephrotoxic contrast agents, offering patients less risk and greater long-term safety. More than 600,000 people at risk in the US alone can benefit from it; saving the health care system up to $8 billion annually.
Clinical studies encompassing over 200 patients have documented zero procedural complications, establishing a robust safety profile supported by the following peer-reviewed evidence:
J Cardiovasc Magn Reson. 2020 Mar 26;22(1):20
Invasive cardiovascular magnetic resonance (iCMR) for diagnostic right and left heart catheterization using an MR-conditional guidewire and passive visualization in congenital heart disease.
Veeram Reddy SR, Arar Y, Zahr RA, Gooty V, Hernandez J, Potersnak A, Douglas P, Blair Z, Greer JS, Roujol S, Forte MNV, Greil G, Nugent AW, Hussain T.
J Cardiovasc Magn Reson 23, 95 (2021)
R. et al. Fick versus flow: a real-time invasive cardiovascular magnetic resonance (iCMR) reproducibility study.
Arar, Y., Hussain, T., Abou Zahr
Cardiovasc Diagn Ther. 2021 Dec;11(6):1356-1366
Real-time CMR guidance for intracardiac and great vessel pressure mapping in patients with congenital heart disease using an MR conditional guidewire-results of 25 patients.
Meierhofer C, Belker K, Shehu N, Latus H, Mkrtchyan N, Naumann S, Martinoff S, Stern H, Eicken A, Ewert P.
physicians.
Seamless Transition to iMRI
Our devices are designed to give physicians a familiar workflow while opening the door to a new era of interventional MRI. The platform supports a wide range of diagnostic and therapeutic procedures where precision and safety are paramount.
By mirroring the cath-lab experience, trackr.ai makes the transition from fluoroscopy to iMRI intuitive and seamless. Physicians can navigate devices in real time with AI-powered guidance, gaining enhanced three-dimensional visualization of anatomy and instruments—without exposing patients or staff to radiation and with minimal use of contrast agents.
This evolution in workflow preserves the efficiency of established catheter-based procedures while enabling safer, more precise interventions. For physicians, it means extending therapeutic options, improving patient outcomes, and shaping the future of minimally invasive care.
about us.
Driving the future of interventional MRI
Who we are?
We are a Medtech company pioneering innovative solutions for MRI-guided interventions. By combining the strengths of nanotechnology and artificial intelligence, we develop technologies that enable MRI guidance of devices for more precise, safer, radiation-free procedures.
Our portfolio supports both clinical applications and translational research, advancing the future of minimally invasive therapies. We collaborate closely with leading healthcare institutions and research centers across Europe and North America to bring our innovations into practice.
Your Health –
Our Vision
We are committed to transforming MRI from a purely diagnostic tool into a true interventional modality—through trusted partnerships and innovative solutions that empower clinicians to perform safer, more precise procedures and deliver better outcomes for patients worldwide
Among the top 3% European innovators
Recognized as a top 3% innovator in Europe, our company was selected by the European Innovation Council to receive the Accelerator Grant—awarded for breakthrough technologies and strong growth potential.
Worlds First. FDA-cleared MRI guidewire
EmeryGlide is the first and only MRI-compatible guidewire with FDA clearance, breaking open access to interventional MRI procedures and creating a new market segment.
Proven
Safety
To date, we have performed 250 right heart catheterizations for pulmonary pressure assessment, achieving a 100% safety record with zero complications.
17 Dedicated Professionals, One Mission
We have a fantastic team of 17 professionals united by the drive to advance our innovative trackr. technology.
Rudolf Schulze Vohren
Co-founder and CEO
He is a serial entrepreneur. 18 years in international management at Bayer AG; founder of five healthcare and life sciences companies.
Prof. Dr. Paul Borm
Co-founder & Former CTO
And the chair of the scientific advisory board. He is an expert in nanotechnology, medical imaging, and has authored over 250 publications.
Cansu Ahlemeyer
CFO
Has extensive experience in finance and analytics, business operations, and startup environments within the Metro Group and LIXIL Corporation.
Lucien de Mos
COO
Has worked with multiple device companies and software firms including Edwards, Toshiba, Pie Medical, and MEDIS, bringing strong expertise in clinical and radiology processes.
Dr. Ing. Samuel Mueller
CTO
Has a strong signature in AI image signal processing and surgical navigation as well as a background in large scale production of medical devices (e.g. Teleflex).
Natalie Theisen
Head of regulatory and quality
She brings experience from similar positions in optical devices and software at Ceramoptec, Fritz Ruck, and Localite.
contact.
How Can We Help?
For quotes, ordering information or questions about one of the products of Nano4Imaging GmbH, please fill in our contact form and we will reply to you as soon as possible.